Cancer cells ensure their uncontrolled growth by heavily leaning on anti-apoptotic proteins like MCL1. Targeting MCL1 rapidly pushes cancer cells down the irreversible path to death.
MCL1 is a key component in cancer cell survival and the one of the main cause for resistance to current standard of care. Targeting MCL1 rapidly induces to apoptotic pathway and irreversible path to cancer cell death. Targeting MCL1 has been accepted as attractive treatment option for cancer patients, yet first generation inhibitors failed due to on target cardiotoxicity. TruelineTx scientists led 10+ years of research to identify TTX-810, the next generation MCL1 inhibitor which leverages anti-tumor activity while avoiding on-target toxicities. TTX-810 selectively inhibits MCL1 function and induces rapid and specific killing of cancer cells in preclinical models when administered as a single agent or in combination with other targeted therapies. Now, it’s full steam ahead to bring this powerful therapeutic agent to patients.
